SC 13G: OnKure Therapeutics, Inc.
Ticker: OKUR · Form: SC 13G · Filed: Nov 14, 2024 · CIK: 1637715
Sentiment: neutral
Topics: sc-13g
AI Summary
SC 13G filing by OnKure Therapeutics, Inc..
Risk Assessment
Risk Level: low
Filing Stats: 1,093 words · 4 min read · ~4 pages · Grade level 10.6 · Accepted 2024-11-14 10:11:45
Key Financial Figures
- $0.0001 — me of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securitie
Filing Documents
- p24-3243sc13g.htm (SC 13G) — 46KB
- 0000902664-24-006543.txt ( ) — 48KB
(a)
Item 1(a). NAME OF ISSUER: The name of the issuer is Reneo Pharmaceuticals, Inc. (the " Company ").
(b)
Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES: The Company's principal executive offices are located at 18575 Jamboree Road, Suite 275-S, Irvine, California 92612.
(a)
Item 2(a). NAME OF PERSON FILING: This statement is filed by Highbridge Capital Management, LLC (" Highbridge " or the " Reporting Person "), a Delaware limited liability company and the investment adviser to certain funds and accounts (the " Highbridge Funds "), with respect to the Common Stock (as defined in Item 2(d) below) directly held by the Highbridge Funds. The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the securities reported herein.
(b)
Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE: The address of the business office of the Reporting Person is 277 Park Avenue, 23rd Floor, New York, New York 10172.
(c)
Item 2(c). CITIZENSHIP: Highbridge is a Delaware limited liability company.
(d)
Item 2(d). TITLE OF CLASS OF SECURITIES: Common Stock, par value $0.0001 per share (the " Common Stock ").
(e)
Item 2(e). CUSIP NUMBER: 75974E103 Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A: (a) ¨ Broker or dealer registered under Section 15 of the Act, (b) ¨ Bank as defined in Section 3(a)(6) of the Act, (c) ¨ Insurance Company as defined in Section 3(a)(19) of the Act, (d) ¨ Investment Company registered under Section 8 of the Investment Company Act of 1940, CUSIP No. 75974E103 13G Page 4 of 6 Pages (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E), (f) ¨ Employee Benefit Plan or Endowment Fund in accordance with Rule 13d1(b)(1)(ii)(F), (g) ¨ Parent Holding Company or control person in accordance with Rule 13d1(b)(1)(ii)(G), (h) ¨ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act, (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act, (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: ________________________________________________________ Item 4. The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page of the Reporting Person and is incorporated herein by reference. The percentages set forth herein are calculated based upon 33,428,808 shares of Common Stock reported to be outstanding as of August 19, 2024, as reported in the Company's Prospectus filed pursuant to Rule 424(b)(3) with the Securities and Exchange Commission on August 26, 2024. Item 5. Not applicable. Item 6. See Item 2. The Highbridge Funds ha
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of our knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct. DATED: November 14, 2024 HIGHBRIDGE CAPITAL MANAGEMENT, LLC By: /s/ Kirk Rule Name: Kirk Rule Title: Executive Director